Drug Trial Radar · NCT07318155
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Mar 11, 2025
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Sirius Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.
Conditions
- Coronary Artery Disease (CAD)
- Peripheral Arterial Disease
Interventions
SRSD107Drug
Administered S.C.
0.9 % sodium chlorideDrug
Administered S.C.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in time-averaged FXI antigenTime frame: 72 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fuwai Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.